Alnylam raises $700M in follow-on

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) raised $700 million late Monday through the sale of 5.6 million shares at $125 in a bumped-up follow-on underwritten by Goldman Sachs, JPMorgan, Barclays, Credit Suisse, Piper Jaffray, JMP Securities, Needham, Chardan and B. Riley FBR. The company proposed to raise $675 million before the market opened on Monday (see BioCentury Extra, Nov. 13).

By year end, Alnylam plans to submit an NDA to FDA and MAA to EMA for patisiran (ALN-TTR02) to treat familial amyloidotic polyneuropathy (FAP), a form of transthyretin (TTR) amyloidosis...